Thanks Midas for starting the mb here.
As I mention I like the co for few reasons
1. It has 2 NDAs coming in next 6 months
2. Many small companies are getting hit by clinical trial delays. This co is out of it.
3. The clinical trial delays are going to be long, hospitals will take many months to come back to normal and start the trials back, in some cases enroll more patients as some of the patients have lost few follow up visits.
Based on this I am focused on small pharma or biotechs who have finished their trials or submitted NDAs
4. The co has money to sustain
5. The 2 drugs of approved will become new SOC. Both indications are facial ones so it has ready market and will have pricing power.
The key is - investor has to hold for at least 1 year for first approval and another 6 months for next approval. During this period one can get this stock at lower price as well.
At $168 million market cap it has at least 3 bagger potential in mind from current price in 2 years.
“Our goals for 2020 are no less ambitious as we plan to file two New Drug Applications (NDA) in the U.S. – Epsolay in the second quarter of 2020 and Twyneo in the second half. In parallel, we are planning commercialization efforts and advancing development of our proprietary pipeline, while benefiting from our strong generic collaborations.” “
In terms of COVID-19 impact,” continued Dr. Seri-Levy, “given that Sol-Gel has completed the clinical programs required to support the NDAs for both Epsolay and Twyneo, and given that Sol-Gel recently strengthened its balance sheet, we remain on track to file both NDAs in the previously communicated timelines.”
Market Data 
Markets 
AI
